Eterna Therapeutics LLC

→ You know how we told you last week that we’d keep our eyes peeled for where ex- Roche Pharmaceuticals CEO Bill Anderson turns up next? Well, he gave us an answer in a big way. Anderson will be the CEO at Bayer starting April 1, the German pharma said Wednesday. Unlike Roche , Merck , J&J and the CEO transition that follows, Bayer chose not to go in-house for Werner Baumann ’s replacement. Investors have been grumbling about the company’s stock performance, so much so that activist investor Jeff Ubben rallied the troops to find someone outside the company to take control. In the end, the investors won. Shares $BAYRY jumped 6% when news circulated about Anderson’s hiring. Baumann’s retirement after 35 years at Bayer, seven of those as CEO, marks another major change in its leadership. Marianne De Backer , Bayer’s wheeler-dealer who engineered the acquisitions of AskBio and Vividion , will replace George Scangos as CEO of Vir Biotechnology on April 3. → Astellas will do some shifting of its own, starting at the top with the April 1 departure of Kenji Yasukawa , the president and CEO since 2018. Chief strategy officer Naoki Okamura will take the helm while EVP of corporate strategy Adam Pearson will be elevated to Okamura’s old post. It doesn’t stop there: Chief commercial officer Yukio Matsui will also retire at the same time as Yasukawa, and Claus Zieler — Astellas’ president, established markets commercial — is set to take Matsui’s place. The extensive C-suite shakeup comes as Astellas says a patent cliff and declining revenue are behind it, and the company is ready to go for “aggressive” growth. It also follows the retirement of CMO Bernhardt Zeiher , who spoke with Amber Tong in August 2022 about the gene therapy AT132 for X-linked myotubular myopathy that Astellas picked up from Audentes — and is linked to multiple patient deaths that shook the entire gene therapy landscape. Since Tadaaki Taniguchi succeeded Zeiher on Oct. 1, Astellas scooped up two gene therapy programs from struggling Taysha and saw a clinical hold get lifted for its Pompe disease gene therapy candidate AT845 . → Previously known as miRagen , Viridian Therapeutics drew in some serious coin once it trotted out Phase I/II data for its thyroid eye disease drug VRDN-001 in August 2022. But after that $270 million offering, Viridian will have a different conductor leading the way, with Jonathan Violin handing the orchestra to new president and CEO Scott Myers . You may remember Myers from his days as CEO of AMAG Pharmaceuticals , the Makena maker that was sold to Covis Pharma back in 2020. He’s also been chief executive at Rainier Therapeutics and Cascadian Therapeutics . → Everything’s coming up Alnylam at super-stealthy Feng Zhang upstart Aera Therapeutics , which has tapped Akin Akinc as CEO and John Maraganore as chairman, Business Insider reports . Akinc takes the helm at the gene editing biotech after ending his 19 years at the RNAi titan in September 2022 as head of oncology. Maraganore has populated Peer Review with an endless array of board appointments and advisory roles ever since he stepped down from the top spot at Alnylam. → A spokesperson for Merck tells Endpoints News that Iya Khalil will join the pharma giant on Feb. 13 as VP and head of data, AI & genome sciences. In a LinkedIn post, Khalil bid farewell to Novartis , where she was global head of the AI innovation laboratory since May 2020. “I want to thank Novartis and all of my colleagues for the unique opportunity to launch the AI lab and NIBR ’s commitment to the continued efforts of the AI team under the exceptional leadership of Fiona Marshall ,” she wrote. Turnabout is fair play here: Novartis plucked Marshall from Merck to replace Jay Bradner as president of NIBR last fall. Merck has been diving deeper into AI through recent partnerships with Absci , BigHat Biosciences and Saama . → STAT writer (and friend of Peer Review) Jason Mast revealed Kathy High ’s departure from AAV gene therapy developer AskBio this week. High co-founded Spark Therapeutics and cemented her legacy in the field with her work on the retinal disease drug Luxturna , the first gene therapy to receive FDA approval. Roche ponied up $4.3 billion for Spark, and High then bolted for AskBio in January 2021, becoming the Bayer sub’s president of therapeutics. STAT indicates that High is on sabbatical at Rockefeller University. → What little remains of Flagship ’s Rubius is still scrambling to determine next steps, and while its strategic review rolls on, CEO Dannielle Appelhans ’ tenure has been extended from Jan. 31 to “no later than March 3,” an SEC filing states . Meanwhile, it’s Laurence Turka ’s turn to leave Rubius after three years as CSO and head of research and translational medicine. Finally, ex-Novartis head of oncology Susanne Schaffert , Francis Cuss and Michael Rosenblatt have all resigned from the board of directors. → TCR biotech T-knife Therapeutics made some noise in 2021 with $110 million in Series B financing and several key hires, including COO Megan Baierlein and CSO Peggy Sotiropoulou . This week T-knife is back with Behzad Kharabi as CMO. Kharabi left J&J for Gilead ’s Kite in 2018 and rose to global program clinical lead for Tecartus , the CAR-T therapy that was first approved in the summer of 2020 for relapsed or refractory mantle cell lymphoma. Tecartus then scored another FDA nod a year later for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. → An SEC filing shows that 2seventy bio COO Nicola Heffron will pack her bags on March 10. No specific reason was given other than the standard line that it wasn’t “due to any disagreement with the Company on any matter.” A Celgene and Shire vet, Heffron jumped over to bluebird bio ’s cancer spinout when Nick Leschly split bluebird into the two separate companies in 2021. She started at bluebird in January 2020 as SVP, Europe. → With apologies to Boz Scaggs , the inability of Adagio Therapeutics ’ Covid-19 antibody to put up a defense against the Omicron variant signaled a breakdown dead ahead for the Tillman Gerngross biotech. Gerngross gave up his spot as CEO, the company rebranded as Invivyd , layoffs ensued , and multiple execs walked out the door. The latest is CSO Laura Walker , who co-founded Adagio and has also worked at Adimab (another Gerngross joint). Interim head of discovery and preclinical Lukas Dillinger will handle CSO duties until Invivyd finds her replacement. → Only a year into his tenure as head of R&D and medical affairs and CMO at Sobi , Anders Ullman has decided to retire on April 1. Tony Hoos , who will take over for the 67-year-old Ullman, has led the global rare disease business unit at GSK and is the former head of medical in Europe for Amgen . Additionally, Hoos spent a year as medical chief of Flagship’s Valo Health . Ullman was a board member at Sobi before he replaced Ravi Rao , the current CMO with Oxford Biomedica and Sitryx . → On April 1, Laetitia Rouxel will become the CFO of German-based Evotec , which boasts a slew of discovery partnerships from a who’s who in the pharma world — Eli Lilly , Boehringer Ingelheim , Novo Nordisk and Bristol Myers Squibb among them. An 11-year Pfizer vet, Rouxel has been divisional finance chief for beauty and fragrance company Coty and global CFO of Dutch plastic pipe provider Wavin . Enno Spillner , Evotec’s CFO since 2016, is leaving at the end of next month when his contract runs out. → Scholar Rock ’s first-year CEO and ex- Acceleron R&D chief Jay Backstrom has lined up a familiar face to take on the role of chief commercial officer. Tracey Sacco joined Acceleron in 2012 as senior director, corporate development and would later work on the product launch of the Bristol Myers-partnered drug Reblozyl . She was SVP, global strategic marketing when Merck bought the biotech for $11.5 billion in the fall of 2021. Scholar Rock hasn’t evaded the onslaught of layoffs in the industry, trimming 25% of its staff in May 2022. → Friedreich’s ataxia specialist Larimar Therapeutics has appointed Gopi Shankar as chief development officer. Shankar just had a 12-year run at J&J and had been Janssen ’s VP and global head, biologics development sciences since 2018. Larimar waited out a clinical hold for its Friedreich’s ataxia candidate CTI-1601 that lasted more than a year until it was lifted in September 2022 . However, a partial hold on the drug is still in place. → Another hire has bubbled up at T cell engager biotech Lava Therapeutics , with Charles Morris taking the CMO reins from Benjamin Winograd . Morris recently held the same title at Celyad Oncology , a biotech hanging on by its fingernails after cutting the cord on development of its allogeneic BCMA CAR-T, CYAD-211 . He also spent two years as medical chief of Radius Health , the now-private company acquired by Gurnet Point Capital and Jim Momtazee ’s Patient Square Capital last summer. → Jeremy Levin’s Ovid is bringing in a new duo with the hiring of Manoj Malhotra as CMO and Toshiya Nishi as epilepsy research head. Malhotra, who’s known Levin for some time, joins the team from Eisai’s neurology business group and has prior stints at Mallinckrodt , Novartis and Takeda under his belt. Meanwhile, Nishi comes to the company from Takeda, where he co-invented soticlestat . In his new role, Nishi will be focused on preclinical development, specifically KCC2. → Going after STAT3 with its lead asset TTI-101 , Houston’s Tvardi Therapeutics has recruited John Kauh as CMO. As VP of clinical development at Hutchmed , Kauh worked on surufatinib , a drug that got dinged with a CRL last year as part of the FDA’s broader clampdown on China-only trial data. Tvardi, co-founded by the University of Texas MD Anderson Cancer Center’s Ron DePinho , last raised cash in June 2021 with a $74 million Series B . → New York cancer biotech Treadwell Therapeutics has welcomed Roger Sidhu as CMO. Sidhu previously showed up in Peer Review when he left Roivant in September 2021 to become medical chief at Brooklyn ImmunoTherapeutics , now named Eterna Therapeutics . Sidhu was VP of clinical development at Kite before landing the CMO and head of R&D posts at Roivant in 2020. → David Gaiero has been promoted to CFO of Cyteir Therapeutics , which laid off 70% of its staff last month and is down to 15 employees who will redouble the Lexington, MA biotech’s efforts in ovarian cancer with a combo therapy of CYT-0851 and capecitabine . Gaiero was named VP of finance at Cyteir in December 2020 after three years as VP, corporate controller and interim CFO at Wave Life Sciences . → Back in September, Palisade Bio downsized its team of 13 by 20% to keep pushing forward with development of its lead candidate. Now, the Carlsbad, CA-based company is promoting Robert McRae to the position of COO. McRae has been with the company since December 2021, having joined as SVP, operations and strategic development. Prior to Palisade, McRae was with Viracta Therapeutics as VP, operations & strategic alliances. In addition to McRae’s promotion, interim CEO JD Finley is grabbing a seat on the company’s board of directors. → JP Gabriel has been named chief technical operations officer at RNAi player Silence Therapeutics after the retirement of SVP, technical operations and Ferring vet Jørgen Wittendorff . Gabriel has held positions in manufacturing and quality at Roche/ Genentech , Ultragenyx and most recently, Ocugen , where he was SVP, technical operations. Almost a year ago, Craig Tooman succeeded Mark Rothera as Silence’s CEO in a shakeup that involved the promotion of Rhonda Hellums to Tooman’s old CFO job. Rothera now runs the show at Viracta Therapeutics. → Shanghai MicuRx Pharmaceutical has pulled in Regis Vilchez as CMO of its American subsidiary, MicuRx Pharmaceuticals . Vilchez is bringing with him experience from Boehringer Ingelheim, Merck, Roche, Abbott / AbbVie and Mallinckrodt . During his career, Vilchez has contributed to the global development of a number of therapies, including Victrelis , Ocaliva and StrataGraft . → Didier Vingadassalom gets his own cadenza in this portion of Peer Review as senior director, business development at Concerto Biosciences . Vingadassalom is a Sanofi alum who comes from SQZ Biotechnologies , where he was senior director, business development and head of alliance management. Co-founded by CEO Cheri Ackerman and CSO Jared Kehe — both trained pianists — microbe-focused Concerto hit the stage three months ago with $23 million in Series A funding . → Blue Water Vaccines , which back in August ditched SPAC merger plans , has reeled in Frank Jaeger as SVP of marketing and business development. Jaeger hails from Clarus Therapeutics , where he was SVP and CCO. Before that, Jaeger was with the team at AbbVie, helping launch AndroGel from its men’s health business unit. → Biren Amin has joined the board of directors at ImmPACT Bio , a CAR-T outfit chaired by ex- Gossamer Bio CEO Sheila Gujrathi . Since leaving Jefferies in 2021, Amin has been finance chief at Immuneering and now tackles the roles of CFO and chief strategy officer for Pyramid Biosciences . → Ex- Blueprint Medicines chief Jeff Albers has been named chairman of the board at MOMA Therapeutics , a Third Rock biotech that raised $150 million in a Series B round last May. Albers, who’s still chairman at Blueprint, started a gig at Atlas Venture last month as a venture partner. → In its first Peer Review appearance since buying Antares Pharma for just shy of $1 billion last April, Halozyme has elected Barbara Duncan to the board of directors. Duncan was CFO of Intercept from 2009-16 and chairs the board at Fusion Pharmaceuticals . → Touting a Phase II win with the ex-Amgen drug obicetrapib last month, NewAmsterdam Pharma has elected John Smither to the board of directors. Smither is an Amgen vet whose past CFO appointments include Sienna Biopharmaceuticals (two separate stints), Kite (interim) and Arcutis . → Sam Truex’ s Upstream Bio flowed onto our radar with a $200 million debut last June, and this week the inflammatory disease biotech has reserved space for Tectonic Therapeutic CMO Marcella Ruddy on the board of directors. To conclude her five years at Regeneron , Ruddy was VP, clinical development for inflammation and immunology from 2018-21. → Waypoint Holdings chairman and CEO Thomas Dietz is headed to the board of directors at RNA player Nutcracker Therapeutics . Dietz, the chairman of Eiger BioPharmaceuticals , owns board seats at Paratek Pharmaceuticals and Leap Therapeutics . → Carisma Therapeutics , the company that took the spotlight with its CAR-M therapy , is bringing in some firepower from one of its allies to its team. Moderna ’s Lin Guey , who oversees the partnership between the two companies, will be joining Carisma’s scientific advisory board. During her career, Guey has worked at Tessera , Xilio , Shire and Pfizer. → Repligen has named ex- Millipore CEO Martin Madaus to its board of directors. Madaus is a senior operating executive at The Carlyle Group and the former North America president and CEO of Roche Diagnostics . → The chief marketing officer of Evolus , Crystal Muilenburg , is hopping onto the board of directors at Elevai Labs . While at Evolus, Muilenburg has helped lead the re-launch of Jeuveau . Prior to Evolus, Muilenburg was with Sienna Biopharmaceuticals and had a decade-long stint at Allergan . → Acticor Biotech , which recently revised its pipeline to postpone a Phase II study, has pulled out a seat on its board of directors for Patricia Zilliox — who will be replacing Corinne Le Goff . Zilliox serves as president and CEO of Eyevensys and has held roles at Alcon Laboratories and the Clinical Research Institute. → Boston-based Anodyne Nanotech , dealing with microneedle tech, has brought on Jeff Mihm to its board of directors. Mihm formerly served as CEO of Noven Pharmaceuticals .

Pioneering cell therapy leader will direct Stemson’s efforts to develop the first iPSC-derived cell therapy to treat hair loss SAN DIEGO--(BUSINESS WIRE)-- Stemson Therapeutics, a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, announced today that Kevin D’Amour, a veteran cell therapy development expert, has joined Stemson as Chief Scientific Officer. Kevin brings two decades of stem cell-derived cell therapy development experience to the Stemson team. This press release features multimedia. View the full release here: Kevin D'Amour, PhD, Chief Scientific Officer, Stemson Therapeutics (Photo: Business Wire) “We are delighted to have Kevin join our team and bring his extensive experience in cell therapy development,” said Geoff Hamilton, Stemson’s Cofounder and Chief Executive Officer. “He is a pioneer in the field of differentiating stem cells to yield therapeutically relevant cells to treat degenerative diseases. His addition will complement and bolster our world class R&D organization and accelerate our mission to develop a breakthrough hair follicle regeneration cell therapy.” “I am excited and honored to join the Stemson team,” said Kevin. “Stemson’s approach to replace lost hair with de novo follicles has tremendous promise and has the potential to bring true hair replacement therapy to a very large patient population. The company has progressed significantly in the past year and I look forward to working with Stemson’s talented team to rapidly advance the program toward the clinic.” Kevin D’Amour, PhD, was at ViaCyte from 2002 until 2021 and served as the company’s Chief Scientific Officer from 2011 – 2021. At ViaCyte, he led the development of the first stem cell-derived cell therapies designed to replace pancreatic beta cells for the treatment of type 1 diabetes. Under Kevin’s leadership, ViaCyte took three cell therapy products into the clinic. ViaCyte was acquired by Vertex in 2022. After his time at ViaCyte, Kevin was Chief Scientific Officer of Brooklyn ImmunoTherapeutics where he focused on developing cell therapies using mRNA-based cell engineering technology. Kevin is co-author of high-pro in renowned scientific journals and an inventor on over 100 patents in the field of stem cells, cell engineering, and cell therapy. Kevin earned his PhD in Biology from the University of California, San Diego. About Stemson Therapeutics Stemson Therapeutics is a pre-clinical stage cell therapy company founded in 2018 with a mission to cure hair loss by leveraging the regenerative power of Induced Pluripotent Stem Cells. Based on the breakthrough innovation by Stemson Therapeutics co-founder, Dr. Alexey Terskikh, Stemson uses iPSC to regenerate the critical cells required to grow hair and which are damaged or depleted in patients suffering from hair loss. The iPSC-derived cells are used to grow de novo hair follicles, offering a new supply of hair to treat people suffering from various forms of Alopecia. Today, there are no available treatments capable of growing new hair follicles. Stemson’s world class team of scientists, advisors and collaborators are passionate about delivering a scientifically based, clinically tested cure for hair loss to the millions of hair loss sufferers who seek help for their hair loss condition. Stemson Therapeutics is headquartered in San Diego, CA. For more information, please visit .

The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Exacis’ iNK and iT cells, made using non-viral, episome-free cell engineering technology, include advanced ‘stealthing’ edits, and can target virtually any cancer antigen SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced it has entered into an option agreement with Exacis Biotherapeutics Inc. (“Exacis”) granting Eterna the right to negotiate an exclusive, worldwide license to develop and commercialize up to four iPS cell-derived natural killer cell (“iNK”) and/or T cell (“iT”) programs for hematologic malignancies and solid tumors. “Exacis’ preclinical data, presented earlier this year at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), provide compelling evidence that its iNK and iT cells exhibit the characteristics needed for the development of next-generation off-the-shelf iPS cell therapies for the treatment of cancer,” said Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna. Exacis makes its cells using non-viral, mRNA-based cell engineering, including a proprietary ‘stealthing’ approach designed to increase the persistence of therapeutic cells in vivo and minimize or eliminate the need for patient pre-conditioning. Exacis’ technology includes high-yield manufacturing processes and the ability to add advanced targeting molecules, including CARs and TCRs. “We believe that Exacis’ approach will be preferred by regulatory authorities over earlier-generation iPS cell technologies, many of which rely on viruses or potentially mutagenic pieces of DNA called episomes,” said Dr. Angel. “We are thrilled to partner with Eterna on these exciting programs,” said Gregory Fiore, M.D., President and CEO of Exacis. Dr. Fiore also serves as a member of Eterna’s board of directors. “We look forward to working with Eterna to bring these novel next-generation iNK and iT cell therapies to patients with cancer who need new treatment options.” Under the agreement, Eterna and Exacis have until December 31, 2022 to negotiate and execute a license agreement. The Company also announced completion of its name change from Brooklyn ImmunoTherapeutics, Inc. to Eterna Therapeutics Inc. About Eterna Therapeutics Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology. Its mission is to realize the potential of cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key cell engineering technologies, including what it believes are the most widely used methods for therapeutic gene editing currently in clinical development. Eterna has multiple next-generation cell and gene-editing therapies in preclinical development for various indications. For more information, please visit . About Exacis Biotherapeutics Exacis is a development stage immuno-oncology company focused on harnessing the human immune system to cure cancer by engineering next generation off-the-shelf NK and T cell therapies aimed at hematologic malignancies and solid tumors. Exacis was founded in 2020 with an exclusive global license to a broad suite of patents covering the use of mRNA based cell reprogramming and gene editing technologies for use in generating engineered NK and T cells for oncology applications. Exacis’ approach avoids the use of DNA and viruses and instead uses a proprietary mRNA based technology. Exacis uses the technology to generate iPSCs and to edit their genome to create stealthed, performance enhanced allogeneic NK and T cell products, termed ExaNK™, ExaCAR-NK™ and ExaCAR-T™ cells. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that are not statements of historical fact and may be identified by terminology such as “believe,” “could,” “estimate,” “anticipate,” “expect,” “plan,” “possible,” “potential,” “project,” “will” or other similar words and the negatives of such words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those stated or implied in any forward-looking statement as a result of various factors, including, but not limited to, uncertainties related to: (i) the evolution of Eterna’s business model into a platform company focused on cellular, gene editing and cytokine programs; (ii) Eterna’s ability to successfully, cost-effectively and efficiently develop its technology and products; (iii) Eterna’s ability to successfully commence clinical trials of any products on a timely basis or at all; (iv) Eterna’s ability to successfully fund and manage the growth of its development activities; (v) Eterna ’s ability to obtain regulatory approvals of its products for commercialization; and (vi) uncertainties related to the impact of the COVID-19 pandemic on the business and financial condition of Eterna, including on the timing and cost of its clinical trials. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this communication speak only as of the date on which they were made, and Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law. Factors that may cause Eterna’s actual results to differ from those expressed or implied in forward-looking statements contained in this press release are more fully disclosed in Eterna’s periodic public filings with the U.S. Securities and Exchange Commission, particularly under the heading “Risk Factors” in Eterna’s Annual Report on Form 10-K for the year ended December 31, 2021, as amended, as well as under similar headings in Eterna’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Investor Relations Contact: investors@eternatx.com Media Contact: Jon Yu ICR Westwicke 475-395-5375 EternaPR@westwicke.com